Self-report scales for schizophrenia

For most of the twentieth century, schizophrenia outcomes were measured exclusively by clinicians. The argument was that insight is reduced in psychosis, that patients cannot reliably introspect on their own symptoms, and that self-report would therefore be unreliable. There is some truth to all of that. But the field has steadily moved toward integrating self-report measures alongside clinician scales, both because patients have a unique window onto their own experience and because measurement-based care at scale is impossible without patient-facing tools. This article surveys the most widely used self-report instruments in modern schizophrenia practice.

The case for self-report

• Patients have direct access to subjective experience that clinicians cannot fully observe (e.g., the felt distress of a voice).
• Self-report is feasible at much higher frequency than clinician interviews — daily or weekly versus monthly.
• It engages patients as collaborators in their own treatment, which has its own therapeutic value.
• It captures domains (recovery, hope, internalised stigma) that clinician scales cannot reach.

The case for caution

• Insight is variable in schizophrenia, particularly during acute episodes.
• Negative symptoms (avolition, blunted affect) are notoriously hard for patients to introspect on.
• Self-report can be affected by mood, fatigue, and time of day.
• Some scales are designed for general population use and may not capture severe psychotic experience well.

The right answer is not "self-report instead of clinician rating" but "both, integrated."

Major self-report instruments

CAPE — Community Assessment of Psychic Experiences

The CAPE is a 42-item self-report scale developed at Maastricht University, used in both general population and clinical research. It rates the frequency and distress of three dimensions: positive psychotic experiences (e.g., perceptual abnormalities, paranoia), negative experiences (e.g., reduced motivation), and depressive experiences. It is freely available and widely used in clinical high-risk research.

PQ-B — Prodromal Questionnaire, Brief version

The PQ-B is a 21-item self-report screen for sub-threshold psychotic experiences. Designed for use in primary care and community samples, it asks "yes/no" about specific experiences and rates distress for each "yes." It is commonly used as a first-stage screen in early-detection programs, with a clinical interview (e.g., SIPS or CAARMS) following positive screens.

BAVQ-R — Beliefs About Voices Questionnaire, Revised

For people who hear voices, the BAVQ-R measures the beliefs they hold about those voices — malevolence, benevolence, omnipotence, resistance, engagement. These beliefs are a major target of CBT for voices. Change on the BAVQ-R is often a stronger marker of clinically meaningful CBTp progress than change in voice frequency alone.

PSYRATS — Psychotic Symptom Rating Scales

Strictly speaking, PSYRATS is interviewer-administered rather than purely self-report — but it relies heavily on patient self-report and is structured around subjective experience. It has separate scales for hallucinations (11 items) and delusions (6 items), each rating frequency, duration, intensity of distress, and degree of negative content. It is widely used in CBTp trials.

QPR — Process of Recovery Questionnaire

Developed in collaboration with people who have lived experience of psychosis, the QPR is a 22-item (or 15-item short) measure of personal recovery. It taps domains like hope, meaning, identity, and personal control. Increasingly used in NHS Early Intervention services in the UK.

RAS — Recovery Assessment Scale

The RAS, in its 24-item form, measures recovery dimensions including personal confidence and hope, willingness to ask for help, goal and success orientation, reliance on others, and not being dominated by symptoms. It is the most widely used recovery measure in US settings.

SNS — Self-Evaluation of Negative Symptoms

One of the few self-report scales designed specifically for negative symptoms. It is brief, has acceptable validity, and is being used increasingly in negative symptom drug development.

CDSS — Calgary Depression Scale (clinician version) and self-report adaptations

The Calgary Depression Scale was specifically designed to measure depression in schizophrenia separately from negative symptoms — a distinction that matters because the treatments are different. The clinician version is the gold standard, but adapted self-report items are used in some measurement-based care programs.

PHQ-9 and GAD-7

For depression and anxiety, the PHQ-9 (depression) and GAD-7 (anxiety) are the most widely used self-report screens in primary and specialty care worldwide. They are generic but well-validated even in serious mental illness populations.

Insight and metacognition scales

• Birchwood Insight Scale — 8-item self-report on awareness of illness, need for treatment, and attribution of symptoms
• Internalized Stigma of Mental Illness (ISMI) — measures how much societal stigma the person has absorbed
• Beck Cognitive Insight Scale (BCIS) — measures self-reflectiveness and self-certainty about beliefs

Functional self-report

Covered in our WSAS article: WSAS, MANSA, and others are short patient-facing measures of how illness is affecting daily life.

Side effect self-report

• Glasgow Antipsychotic Side-effect Scale (GASS) — 22 items, brief, well-suited to outpatient use
• Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) — 51 items, more detailed

Side-effect reporting is one area where self-report is arguably more accurate than clinician observation — patients live with the effects continuously.

Putting it together

A modern measurement-based care bundle for schizophrenia might look like:

• Daily — brief self-report on sleep, voice frequency, distress, mood, medication taken
• Weekly — short multi-domain check (5–10 items)
• Monthly — slightly longer check including functional and recovery items
• Quarterly — clinician-administered scales (BPRS-E, CGI-S/I) at the appointment
• Yearly — broader battery including cognition and metabolic monitoring

What this means for patients and families

If your clinician is not using any kind of structured measurement, asking for it is reasonable. Even a brief monthly self-report (PHQ-9 plus a couple of psychosis items) gives both of you something concrete to talk about. NAMI's guidance on treatment increasingly recommends measurement-based approaches, and many state and national programs now require them.

How Frida thinks about it

The point of patient-facing measurement is not to grade the person — it is to give them visibility into their own pattern. We use brief, validated self-report items that map onto the constructs measured by the major clinician scales discussed in this series. Trends are the unit of value, not single ratings. The goal is a shared, longitudinal record that the patient owns and the clinician can read at a glance.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.